Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Therapeutic Targeting of TP53 mutant Sonic Hedgehog Medulloblastoma
FY 2021-22
Summary
Medulloblastoma is the most common malignant paediatric brain tumour and is currently treated with surgery, external beam radiation and chemotherapy. Current treatments are debilitating to the developing and this is particularly problematic in younger children where radiation results in long-term cognitive dysfunction. A subset of these tumours harbour a TP53 mutation resulting in fatal prognosis where local re-occurrence and radio-resistance is prominent. There is an urgent need to develop faithful models which recapitulate the disease to understand the mechanism of resistance and develop novel targets and therapeutics to sensitize tumours to radiation. The proposed study aims to identify therapeutic and genetic vulnerabilities in response to radiation therapy. I established multiple models which have shown to retain the phenotypic and genotypic characteristics of SHH medulloblastoma. These models recapitulate the human disease demonstrating genomic instability and radiation resistance. Using these unique models, initial results of a high-throughput drug screen revealed a novel class of radio-sensitizers termed bromodomain inhibitors which re-sensitize these high-risk tumours to radiation. Additionally, using a large-scale genomic screen, I have identified essential genes in addition to context-essential genes which confer radiation sensitivity and radiation resistance in our models. Using a combination of high-throughput drug screening and a functional genomic approach I expect to identify the achilles heel of genetic and therapeutic vulnerabilities in response radiation to develop new insights into the biology of treatment resistance within this high-risk group of medulloblastoma. Using this robust approach, I can identify new combinational therapies to enhance current treatments by sensitizing tumours to radiation.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
458267
Name
DeCarlo Alexandria L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Therapeutic Targeting of TP53 mutant Sonic Hedgehog Medulloblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Crispr-Cas9; Epigenetic Screening; Genetic Sequencing; High-Throughput Drug Screening; Medulloblastoma; Radiotherapy; Therapy Sensitization
Abstract
Medulloblastoma is the most common malignant paediatric brain tumour and is currently treated with surgery, external beam radiation and chemotherapy. Current treatments are debilitating to the developing and this is particularly problematic in younger children where radiation results in long-term cognitive dysfunction. A subset of these tumours harbour a TP53 mutation resulting in fatal prognosis where local re-occurrence and radio-resistance is prominent. There is an urgent need to develop faithful models which recapitulate the disease to understand the mechanism of resistance and develop novel targets and therapeutics to sensitize tumours to radiation. The proposed study aims to identify therapeutic and genetic vulnerabilities in response to radiation therapy. I established multiple models which have shown to retain the phenotypic and genotypic characteristics of SHH medulloblastoma. These models recapitulate the human disease demonstrating genomic instability and radiation resistance. Using these unique models, initial results of a high-throughput drug screen revealed a novel class of radio-sensitizers termed bromodomain inhibitors which re-sensitize these high-risk tumours to radiation. Additionally, using a large-scale genomic screen, I have identified essential genes in addition to context-essential genes which confer radiation sensitivity and radiation resistance in our models. Using a combination of high-throughput drug screening and a functional genomic approach I expect to identify the achilles heel of genetic and therapeutic vulnerabilities in response radiation to develop new insights into the biology of treatment resistance within this high-risk group of medulloblastoma. Using this robust approach, I can identify new combinational therapies to enhance current treatments by sensitizing tumours to radiation.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
DeCarlo, Alexandria L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~